by Single-use bioreactors are fully disposable bioreactors that facilitate continuous manufacturing of biologics. They are increasingly being adopted by biopharmaceutical companies due to benefits such as lower capital investment, flexibility in production, reduced risk of cross-contamination, and ease of scale-up or scale-down. Single-use bioreactors are used in the manufacturing of vaccines, recombinant proteins, antibodies, and other biotherapeutics. They find wide applications across R&D, clinical manufacturing, and commercial production activities. The global single-use bioreactor market is estimated to be valued at US$ 1337.67 Mn in 2023 and is expected to exhibit a CAGR of 15% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The growing demand for continuous manufacturing of biologics is expected to drive the growth of the single-use bioreactor market over the forecast period. Continuous manufacturing allows for improved production efficiency, reduced costs, consistent quality, and greater flexibility in operations. It is increasingly being adopted by biopharmaceutical companies as a preferable approach over batch manufacturing. Additionally, the increasing adoption of single-use technologies by small companies and emerging markets is also expected to fuel market growth. While capital expenditure is lower with single-use systems, they require additional operating expenses compared to stainless steel assemblies. However, the operating expense savings achieved through faster development cycles, preventive maintenance, and elimination of cleaning validations outweigh this disadvantage.
Segment Analysis
The Single-Use Bioreactor Market Demand is segmented based on product, cell culture type, molecule type, end user, and region. By product, the market is classified into single-use bioreactor systems, single-use media bags, single-use filtration assemblies, and other products. Among these, the single-use bioreactor systems segment is estimated to dominate the market due to the advantages offered such as low operating costs, easy scalability, flexibility, and reduced risks of product contamination.
PEST Analysis
Political: Regulations supporting cell-based research and biopharmaceutical production have boosted adoption of single-use bioreactors. However, trade policies can impact supply of raw materials.
Economic: Cost advantages of single-use bioreactors over stainless steel bioreactors is a key driver. Rapid growth in biopharma industry also fuels demand.
Social: Increased research on disease modeling and cell & gene therapies has increased acceptance of single-use technologies. Aging population boosts healthcare expenditure.
Technological: Advanced single-use sensors and controllers have enhanced process understanding and capability. Digitalization of bioprocessing aids data-driven optimization.
Key Takeaways
The global single-use bioreactor market is expected to witness high growth during the forecast period. Regionally, North America is expected to dominate the market owing to significant R&D investments and a large base of pharmaceutical and biotechnology companies in the region. Some of the key players operating in the single-use bioreactor market are Sartorius AG, OmniBRx Biotechnologies, Merck KgaA, Solaris Biotechnology Srl, Eppendorf AG, Distek Inc., Celltainer Biotech BV, ABEC Inc., Thermo Fisher Scientific, and Danaher Corporation (Pall Corporation), among others. Key players are focusing on new product launches and facility expansions to strengthen their market position.
Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
